856 related articles for article (PubMed ID: 23339124)
1. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B
Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124
[TBL] [Abstract][Full Text] [Related]
2. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer.
Escudier B; Grünwald V; Ravaud A; Ou YC; Castellano D; Lin CC; Gschwend JE; Harzstark A; Beall S; Pirotta N; Squires M; Shi M; Angevin E
Clin Cancer Res; 2014 Jun; 20(11):3012-22. PubMed ID: 24691021
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II and pharmacodynamic study of dovitinib (TKI258), an inhibitor of fibroblast growth factor receptors and VEGF receptors, in patients with advanced melanoma.
Kim KB; Chesney J; Robinson D; Gardner H; Shi MM; Kirkwood JM
Clin Cancer Res; 2011 Dec; 17(23):7451-61. PubMed ID: 21976540
[TBL] [Abstract][Full Text] [Related]
4. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Motzer RJ; Porta C; Vogelzang NJ; Sternberg CN; Szczylik C; Zolnierek J; Kollmannsberger C; Rha SY; Bjarnason GA; Melichar B; De Giorgi U; Grünwald V; Davis ID; Lee JL; Esteban E; Urbanowitz G; Cai C; Squires M; Marker M; Shi MM; Escudier B
Lancet Oncol; 2014 Mar; 15(3):286-96. PubMed ID: 24556040
[TBL] [Abstract][Full Text] [Related]
5. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer.
André F; Bachelot T; Campone M; Dalenc F; Perez-Garcia JM; Hurvitz SA; Turner N; Rugo H; Smith JW; Deudon S; Shi M; Zhang Y; Kay A; Porta DG; Yovine A; Baselga J
Clin Cancer Res; 2013 Jul; 19(13):3693-702. PubMed ID: 23658459
[TBL] [Abstract][Full Text] [Related]
6. Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Dubbelman AC; Upthagrove A; Beijnen JH; Marchetti S; Tan E; Krone K; Anand S; Schellens JH
Cancer Chemother Pharmacol; 2012 Nov; 70(5):653-63. PubMed ID: 23010851
[TBL] [Abstract][Full Text] [Related]
7. A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Powles T; Foreshew SJ; Shamash J; Sarwar N; Crabb S; Sahdev A; Nixon J; Lim L; Pungaliya A; Foreshaw A; Davies R; Greenwood M; Wilson P; Pacey S; Galazi M; Jones R; Chowdhury S
Eur J Cancer; 2014 Aug; 50(12):2057-64. PubMed ID: 24908540
[TBL] [Abstract][Full Text] [Related]
8. Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Cheng AL; Thongprasert S; Lim HY; Sukeepaisarnjaroen W; Yang TS; Wu CC; Chao Y; Chan SL; Kudo M; Ikeda M; Kang YK; Pan H; Numata K; Han G; Balsara B; Zhang Y; Rodriguez AM; Zhang Y; Wang Y; Poon RT
Hepatology; 2016 Sep; 64(3):774-84. PubMed ID: 27082062
[TBL] [Abstract][Full Text] [Related]
9. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.
Porta C; Giglione P; Liguigli W; Paglino C
Future Oncol; 2015; 11(1):39-50. PubMed ID: 25572783
[TBL] [Abstract][Full Text] [Related]
10. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
[TBL] [Abstract][Full Text] [Related]
11. An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer.
Lim SM; Chung WY; Nam KH; Kang SW; Lim JY; Kim HG; Shin SH; Sun JM; Kim SG; Kim JH; Kang CW; Kim HR; Cho BC
Eur J Cancer; 2015 Aug; 51(12):1588-95. PubMed ID: 26070683
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
[TBL] [Abstract][Full Text] [Related]
15. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Kang SK; Volodarskiy A; Ohmann EL; Balar AV; Bangalore S
Clin Oncol (R Coll Radiol); 2016 May; 28(5):334-41. PubMed ID: 26723100
[TBL] [Abstract][Full Text] [Related]
17. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Konecny GE; Finkler N; Garcia AA; Lorusso D; Lee PS; Rocconi RP; Fong PC; Squires M; Mishra K; Upalawanna A; Wang Y; Kristeleit R
Lancet Oncol; 2015 Jun; 16(6):686-94. PubMed ID: 25981814
[TBL] [Abstract][Full Text] [Related]
18. Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Mancuso A; Di Paola ED; Leone A; Catalano A; Calabrò F; Cerbone L; Zivi A; Messina C; Alonso S; Vigna L; Caristo R; Sternberg CN
BJU Int; 2012 Jan; 109(2):200-6. PubMed ID: 22212284
[TBL] [Abstract][Full Text] [Related]
19. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients.
Ma WW; Xie H; Fetterly G; Pitzonka L; Whitworth A; LeVea C; Wilton J; Mantione K; Schihl S; Dy GK; Boland P; Iyer R; Tan W; Brady W; Straubinger RM; Adjei AA
Am J Clin Oncol; 2019 Feb; 42(2):184-189. PubMed ID: 30418178
[TBL] [Abstract][Full Text] [Related]
20. Third-line dovitinib in metastatic renal cell carcinoma.
Schmidinger M
Lancet Oncol; 2014 Mar; 15(3):245-6. PubMed ID: 24556039
[No Abstract] [Full Text] [Related]
[Next] [New Search]
